Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months.

Abstract

OBJECTIVE The objective of the study was to evaluate whether tumor shrinkage or GH and IGF-I levels achieved after 3 months predicted tumor shrinkage after 12 months of octreotide-long-acting release (LAR) treatment. PATIENTS Patients included 67 patients with de novo acromegaly (33 women, 34 men; aged 20-82 yr) receiving LAR at a dose of 20 mg every 28 d… (More)
DOI: 10.1210/jc.2008-0424

Topics

Cite this paper

@article{Colao2008GrowthHT, title={Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months.}, author={Annamaria Colao and Rosario Pivonello and Renata Simona Auriemma and Mariano Galdiero and Silvia Savastano and Ludovica Francesca Stella Grasso and Gaetano Lombardi}, journal={The Journal of clinical endocrinology and metabolism}, year={2008}, volume={93 9}, pages={3436-42} }